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Abstract
A total of 73 clinical isolates of extended spectrum β- lactamase producing 
Escherichia coli were sampled in North Lebanon. The ESBL resistance was screened 
using disc diffusion method, while the resistance genes were detected by poly-
merase chain reaction (PCR). The results marked the high prevalence of gene CTX-M 
(72 strains), whereas 33 strains carried the gene OXA, 16 strains carried the gene 
TEM and 3 carried the SHV gene. The majority of the strains carried two or more 
genes. This study points out the high rate of transmission of these genes among 
Escherichia coli strains in North–Lebanon and shows a reduced sensitivity to quino-
lones (pipemidic acid(12.1%); ofloxacin (21.9%) and ciprofloxacin (23.9%), in addition, 
all tested strains were highly susceptible to tigecycline (100%), fosfomycin (98.6%) 
and imipenem (97.2%).
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Introduction
The Enterobacteriaceae is a source of serious threatening dis-
eases worldwide, with the occurrence of Escherichia coli (E. coli) 
secondary to Gram positive cocci (1). Beta-lactam antibiotics 
such as long spectrum cephalosporins and carbapenems are 
the preferred treatment of enterobacterial infections (1). The 
genes of extended spectrum beta-lactamases (ESBLs) are en-
coded by transferable plasmids (2); thus enabling these bacteria 
to acquire ESBL by different resistance mechanisms. In recent 
years, the emergence of β-lactamases worldwide, increased 
the challenge of infections caused by bacteria species carried 
these enzymes (2). Moreover, the excessive and unregulated 
use of antibiotics are the fundamental cause in the selection of 
resistance mechanisms (1). The Enterobacteriaceae producers of 
ESBLs have become a serious problem of public health world-
wide since 1995, because of the increased emergence of new 
variants; especially CTX-M) (3,4). In fact, the majority of the en-
terobacterial infections caused by ESBL producing organisms 
are E. coli and K. pneumoniae strains carrying the CTX-M gene 
responsible for community infections, especially the urinary 
tract infections (1, 5).
The aim of this study is to evaluate the susceptibility of the 
ESBL producing E. coli strains to commonly used antibiotics 
and to detect the presence of the four common ESBL genes: 
TEM, OXA, CTX-M and SHV using PCR method.
Material and Methods
Bacterial Strains. A total of 73 clinical strains were isolated be-
tween the years 2007 and 2009 in the Microbiology depart-
ment of the Nini laboratory hospital in Tripoli, North Lebanon. 
Of these strains, 58 were isolated from urine, 3 from blood, 4 
from bronchial fluid, 6 from deep wounds and 2 from perito-
neal fluid. The strains were identified by the API 20E system 
(bioMérieux® France). A strain of E. coli CMUL 028 sensitive to 
all antibiotics (Collection Microbiologie Université Libanaise) 
was used as control.
The other positive controls used in PCR, were E.coli strains ob-
tained from the Collection d’Institut Pasteur: The CIP 103983 
strain is TEM-4 positive, the CIP 105836 is SHV-1 positive and the 
CIP 103982 strain is CTX-M positive. E.coli strain « Imp 15 » was 
used as positive control for the gene OXA-1 (Table 1).
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Antibiotics Susceptibility
The susceptibility of strains to antibiotics was performed us-
ing the disc diffusion method on Müller-Hinton agar following 
the recommendations of the Comité Antibiogramme, Société 
Française de Microbiologie (CA-SFM) (www.sfm-microbiologie.
org).
The following antibiotic discs were used:
Ampicillin (AMP) (10µg); ticarcillin (TIC) (75 µg); piperacillin (PP) 
(75µg); amoxicillin – clavulanic acid (AUG) (20/10µg); piperacil-
lin-tazobactam (TZP) (75/10µg); cephalexin (CFL) (30µg); ce-
furoxime (CXM) (30µg); cefoxitin (FOX) (30µg); cefixime (FIX) 
(30µg); cefotaxime (CTX) (30µg); ceftazidime (CAZ) (30µg); ce-
fepime (FEP) (30µg); imipenem (IMI) (10µg); tigecycline (TGC) 
(15µg) ; aztreonam (AZM) (30µg); trimethoprim - sulfamethoxa-
zole (STX) (1,25/23,75μg); colistine (Cs) (50µg); ticarcillin - cla-
vulanique acid (TCC) (75/10µg); gentamicin (GEN) (15µg); to-
bramicin (TM) (10µg); amikacin (AMK) (30µg); netilmicin (NET) 
(30µg); nitrofurantoin (FT) (300µg); pipemidic acid (PIP) (20µg); 
pefloxacin (PEF) (5µg); ciprofloxacin (CIP) (5µg); fosfomycin 
(FOS) (50 µg) (BioRad®, France).
The ESBL presence was screened using the disc diffusion 
method on Müller-Hinton agar. The synergy between the cla-
vulanic acid (Beta-lactamases inhibitor) and a third generation 
cephalosporin: cefotaxime, ceftazidime, cefepime, and aztre-
onam, was detected following the recommendations of CA-
SFM (www.sfm-microbiologie.org). The amoxicillin-clavulanic 
acid disc was placed in the center of the plate at a distance of 
25-30 mm between the cephalosporins and the amoxicillin-
clavulanic acid. The clavulanic acid inhibits the production of 
ESBL by E. coli thus forcing sensitivity to cephalosporins upon 
viewing visible expansion of the sensitivity zone by the side 
of clavulanic acid disc, forming a mushroom shape confirms 
the test.
The ESBL genes detection
The detection of gene sequences coding for the TEM, OXA, 
SHV and CTX-M-type enzymes was performed by using a com-
mercial Plasmid Miniprep kit ( GenEluteTM ) (Sigma-Aldrich), fol-
lowing the protocol delivered by the manufacturer. PCR was 
applied using the ready Mix Kit (REDTaq® ReadyMixTM PCR reac-
tion Mix with MgCl2), Sigma - Aldrich, and the primers used to 
amplify the above mentioned genes are listed in table I. Six-
teen strains show none of these 4 genes. The Isoelectric focus-
ing of these 16 strains was performed with a polyacrylamide 
gel containing ampholines with a pH range of 3.5 to 10.0, using 
the Multiphor II flat - bed (Pharmacia Biotech, Uppsala, Swe-
den); 2 hours of migration at 3000 V, 150 mA, 15W)(6). TEM-1 (pI 
5.4), OXA-1 (pI 7.5), CTX-M-14 (PI 7.9) and CTX-M-15 (pI 8.6) were 
used as standards. Molecular screening of blaCTX-M was per-
formed using the primer of CTX-M1 as shown in the Table 1.
Results
The results shown in the Table 2 revealed a predominance of 
the CTX-M gene among the strains of E. coli isolated in North 
Lebanon (32 strains). The majority of the E. coli strains carried 
two or more ESBL genes, and only one strain carried all 4 gene 
types.
Gene type No. of strains
 CTX-M 32
 OXA-1  1
 CTX-M + TEM-1  6
 CTX-M + OXA-1 22
 CTX-M + SHV  2
 CTX-M + OXA + TEM
CTX-M + OXA + TEM-1 + SHV 
 9
1
TABLE 2. CTX-M Genes distribution among 73 tested strains. 
TABLE 1. Primers sequences and PCR cycles performed for each tested gene (8).
R and Y are variable nucleotides. R: Purine (adenine or guanine). Y: Pyrimidine (thymine or cytosine) (http://www.chem.qmul.ac.uk/iubmb/misc/naseq.html)
Primer Primer sequences PCR cycles
TEM-1/F
TEM-1/R
ATGAGTATTCAACATTTCCG
CTGACAGTTACCAATGCTTA
1 cycle of 5 minutes (min) at 96 oC; 35 cycles of [1min at 96oC, 1min at 58 oC, 
1min at 72 oC]; 1 cycle of 10min at 72 oC.
SHV-1/F
SHV-1/R
GGTTATGCGTTATATTCGCC
TTAGCGTTGCCAGTGCTC
1 cycle of 5min at 96 oC; 35 cycles of [1min at 96 oC, 1min at 60 oC, 1min at  
72 oC; 1 cycle of 10min at 72 oC
OXA-1/F
OXA-1/R
ACACAATACATATCAACTTCGC
AGTGTGTTTAGAATGGTGATC
1 cycle 5min at 96 oC; 35 cycles of
[1min at 96 oC, 1min at 60oC, 2min at 72 oC]; 1 cycle of 10 min at 72 oC
CTX-MU1
CTX-MU2
CTX-M1-A2
CTX-M1- B2
ATGTGCAGYACCAGTAARGT
TGGGTRAARTARGTSACCAGA
CTT CCA GAA TAA GGA ATC
CCG TTT CCG CTA TTA CAA
1 cycle of 7 min at 94oC; 35 cycles of
[50seconds (sec) at 94 oC, 40sec at 50 oC, 1min at 72 oC]; 1 cycle of 5min at 72 oC
1 cycle of 10min at 94 oC, 30 cycles of [1min at 94 oC, 1min at 48 oC, 1 min at  
72 oC], 1 cycle of 7min at 72 oC.
The number of strains carrying the CTX-M gene was 72 strains. The number of 
strains carrying OXA-1 was 33 strains. The number of strains carrying only the 
CTX-M gene (32 strains) and only the OXA-1 gene (1 strain) are shown above.
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The isoelectric focusing experiments pointed that 16 strains 
produced β-lactamases of pI 8.6 in addition to their natural re-
spective β-lactamases. The PCR-based analysis of β-lactamase-
encoding genes revealed that all these 16 strains harbored the 
CTX-M1 gene.
Table 3 shows the results of susceptibility to antibiotics for 
the 73 tested E. coli ESBLs producers. The results shows a low 
susceptibility of these strains to quinolones (pipemidic acid: 
12.5%) and fluoroquinolones (ofloxacin;25% and ciprofloxa-
cin;28%). Two of the isolates were resistant to imipenem; the 
first one carried 3 resistance genes (OXA, TEM & CTX-M) and 
the second one carried the CTX-M gene alone.
The susceptibility rates of these strains to the following an-
tibiotics were: amoxicillin - clavulanic acid: 23.3%; ticarcillin - 
clavulanic acid: 23.19%; imipenem 97.2%; tazobactam - piper-
acillin 82.2%; cefoxitin 82.2%; trimethoprim - sulfamethoxazole 
19.2%; amikacin 81.94%; gentamicin 35.2%; tobramycin 23.3%; 
netilmicin 60.9% ; tigecycline 100%; fosfomycin 98.6%; and ni-
trofurantoin 89.7%.
Discussion
The results of the study confirm the high prevalence of CTX-
M gene, while the prevalence of other SHV genes was very 
low (Table 2). Recently, the ESBL distribution in Europe showed 
a dramatic increase of CTX-M gene instead of TEM and SHV 
genes (7). The ESBL production is much less frequent in Europe 
than in Latin America and Asia, and they are even less frequent 
in the Pacific than in North America (7).
Recent European studies on Enterobacteriaceae have also con-
firmed the persistence of strains producing TEM and SHV, and 
the increasing prevalence of strains producing CTX-M (2). Oth-
er types of ESBL such as PER, GES, IBC and some OXA types are 
existing. These genes are mostly detected in Pseudomonas ae-
ruginosa and in Acinetobacter spp.(9). The prevalence of ESBL 
productions revealed a significant geographical differences, 
ranging from 0% (Iceland) to less than 1% (Estonia) to 41% for 
E. coli (Romania) and 91% (Romania) for K. pneumonia (7).
In the past several years, the emergence of new variants of ESBL 
producers, especially CTX-M has suggested the involvement of 
the co-resistance to other drug classes during endemic condi-
tion. This co-resistance is due to the transmission of different 
types of resistance genes within the same clone. Several stud-
ies showed that blaCTX-M genes are commonly found on large 
plasmids that often carry other genes conferring resistance to 
other antimicrobial agents including aminoglycosides, fluoro-
quinolones, chloramphenicols, tetracyclins and others (par-
ticularly, blaOXA-1, blaTEM-1, tetA, aac(6′)-lbcr) (9-11). This may 
explain the high rate of transmission of CTX-M gene among the 
E. coli strains by acquiring R-plasmid, and often the high preva-
lence of the CTX-M resistance gene is combined with another 
resistance genes in these strains.
The CTX-M gene predominates in Europe, while in other coun-
tries, the ESBL genes are more diverse (2,9). In the United King-
dom, a recent dramatic increase of the ESBL producing strains 
was observed both in hospitals and in the community, and this 
increase is attributed to CTX-M-15 (7). In Norway and Portugal, 
the CTX-M is the ESBL enzyme most frequently found in E. coli 
(12-13). In Italy, the prevalence of E. coli producers of ESBL has 
also increased with a predominance of TEM (45.4%), SHV-12 
and the emergence of CTX-M and PER (14). Few of these stud-
ies reported the type of ESBL produced by these strains and 
some showed the presence of TEM, OXA, SHV and the dramatic 
emergence of CTX-M (10,15,16,17).
TABLE 3. Antibiotics Susceptibility of the 73 tested strains.
Antibiotic % Susceptibility
AMP 0
TIC 0
PP 0
AUG 23.3
TZP 82.2
CFL 0
CXM 0
FOX 82.2
FIX 0
CTX 0
CAZ 0
FEP 0
IMI 97.2
TGC  100
ATM 0
SXT 19.2
CS  100
TCC  23.19
GEN 35.2
TM 23.3
AMK  81.94
NET 60.9
FT  89.7
PIP  12.06
PEF/OF 21.9
CIP 23.9
FOS 98.6
ampicillin (AMP), ticarcillin (TIC), piperacillin (PP), amoxicillin – cla-
vulanic acid (AUG), piperacillin - tazobactam (TZP), cephalexin (CFL), 
cefuroxime (CXM), cefoxitin (FOX), cefixime (FIX), cefotaxime (CTX), 
ceftazidime (CAZ), cefepime (FEP), imipenem (IMI), tigecycline 
(TGC), aztreonam (AZM), trimethoprim - sulfamethoxazole (STX), 
colistine (Cs), ticarcillin - clavulanic acid (TCC), gentamicin (GEN), 
tobramicin (TM), amikacin (AMK), netilmicin (NET), nitrofurantoin 
(FT), pipemidic acid (PIP), pefloxacin (PEF), ciprofloxacin (CIP), fosfo-
mycin (FOS).
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The major prevalence of ESBLs was attributed first to K. pneu-
monia strains which have produced TEM and SHV, and then 
followed by the emergence of E. coli strains producers of CTX-
M which become the prevalent type (10,17).
In Turkey, a study conducted by Ozgumus et al. 2007, showed 
that 15% of Enterobacteriaceae isolates are producers of ESBLs. 
The 2 commonly TEM and SHV genes were detected. Of these 
strains, 5 were carrying the gene TEM, 12 were carrying the 
two genes TEM and SHV and 3 were negative for both of the 2 
genes (18). Also, Kiratisin et al.2008 in Taїland, have studied 235 
strains of E. coli producers of ESBLs, and found that 87.3 % of 
the strains were carriers of the gene CTX-M, 77% were carrying 
TEM gene, and 3.8% were carriers of the gene SHV. In addition, 
few strain produced VEB-1 and OXA-10, and non of the isolate 
produced of PER and GES (19).
The general susceptibility pattern of ESBL producer strains to 
antibiotics has decreased in recent years in many countries 
(15,17,20). However, the present study showed high suscepti-
bility patterns to the most effective antibiotics used against 
E. coli producers of ESBLs. In addition, E.coli producer of ES-
BLs have mostly a reduced susceptibility to the trimethoprim 
- sulfamethoxazole (19.2%), whereas other studies conduct-
ed in Bahrain and in Khartoum have shown different results 
(21,22,23). But on the other site, this study revealed an alarming 
decrease in the susceptibility of our isolates to the quinolones 
and the fluoroquinolones (table 3). Similar results are found in 
a study previously conducted in Lebanon (15), whereas other 
studies carried out in the Middle East areas have shown higher 
susceptibility rates of their isolates to fluoroquinolones (23, 24).
It is important to note that 23.3% of our isolates were suscep-
tible to the clavulanic acid associated with the amoxicillin or 
ticarcillin, whereas this percentage increased significantly in 
the case of tazobactam associated with the piperacillin (82.2%). 
Our results show a similarity with a study conducted by Oliver 
et al. 2002 (25). The susceptibility of our isolates to cefoxitin 
was 82.2%, which is similar to the results of study performed 
in Iran by Mehrgan et al. 2008 (24).
With regards to the aminoglycosides, our results showed that 
amikacin remains the most active drug (81.4%). Kader et al. 
2005, have shown similar results in their study conducted in 
Saudi Arabia (27). The susceptibility of gentamicin and to-
bramycin was low (35.2%, 23.3%) respectively, in comparison 
to study carried out in recently in Sudan which has reported 
higher susceptibility to aminoglycosides (23).
Among the 73 strains of E. coli producers of ESBLs, 58 (79.5%) 
were isolated from urine; which indicates the highly occurrence 
of these strains in urinary tract infections. A previous study 
from the Calgary Health Region in Canada, demonstrated that 
CTX-M - producing E. coli is emerging as an important cause of 
community- onset urinary tract infections (28,29).
It should be noted that the percentage of E. coli resistance to 
ampicillin, aminoglycosides, tetracycline, chloramphenicol and 
sulphonamides are lower in the industrialized countries than in 
the developing countries (11), since the overuse and the uncon-
trolled use of antibiotics and the low standard of personal and 
community hygiene are favoring the spread of resistant strains 
between humans in the developing countries.
The results of the study confirm the high prevalence of CTX-
M gene, while the prevalence of other SHV genes was very 
low (Table 2). Recently, the ESBL distribution in Europe showed 
a dramatic increase of CTX-M gene instead of TEM and SHV 
genes (7). The ESBL production is much less frequent in Europe 
than in Latin America and Asia, and they are even less frequent 
in the Pacific than in North America (7).
Recent European studies on Enterobacteriaceae have also con-
firmed the persistence of strains producing TEM and SHV, and 
the increasing prevalence of strains producing CTX-M (2). Other 
types of ESBL such as PER, GES, IBC and some OXA types are 
exist. These genes are mostly detected in Pseudomonas ae-
ruginosa and in Acinetobacter spp.(9). The prevalence of ESBL 
productions revealed a significant geographical differences, 
ranging from 0% (Iceland) to less than 1% (Estonia) to 41% for 
E. coli (Romania) and 91% (Romania) for K. pneumonia (7).
In the past several years, the emergence of new variants of ESBL 
producers, especially CTX-M has suggested the involvement of 
the co-resistance to other drug classes during endemic condi-
tion. This co-resistance is due to the transmission of different 
types of resistance genes within the same clone. Several stud-
ies showed that blaCTX-M genes are commonly found on large 
plasmids that often carry other genes conferring resistance to 
other antimicrobial agents including aminoglycosides, fluoro-
quinolones, chloramphenicols, tetracyclins and others (par-
ticularly, blaOXA-1, blaTEM-1, tetA, aac(6′)-lbcr) (9-11). This may 
explain the high rate of transmission of CTX-M gene among the 
E. coli strains by acquiring R-plasmid, and often the high preva-
lence of the CTX-M resistance gene is combined with another 
resistance genes in these strains.
The CTX-M gene predominates in Europe, while in other coun-
tries, the ESBL genes are more diverse (2,9). In the United King-
dom, a recent dramatic increase of the ESBL producing strains 
was observed both in the hospitals and in the community, and 
this increase is attributed to CTX-M-15 (7). In Norway and Por-
tugal, the CTX-M is the ESBL enzyme most frequently found in 
E. coli (12-13). In Italy, the prevalence of E. coli producers of ESBL 
has also increased with a predominance of TEM (45.4%), SHV-12 
and the emergence of CTX-M and PER (14). Few of these stud-
ies reported the type of ESBL produced by these strains and 
some showed the presence of TEM, OXA, SHV and the dramatic 
emergence of CTX-M (10,15,16,17).
The major prevalence of ESBLs was attributed first to K. pneu-
monia strains which have produced TEM and SHV, and then 
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followed by the emergence of E. coli strains producers of CTX-
M which become the prevalent type (10,17).
In Turkey, a study conducted by Ozgumus et al. 2007, showed 
that 15% of Enterobacteriaceae isolates are producers of ESBLs. 
The 2 commonly TEM and SHV genes were detected. Of these 
strains, 5 were carrying the gene TEM, 12 were carrying the 
two genes TEM and SHV and 3 were negative for both of the 
2 genes (18).
In Taїland, Kiratisin et al.2008, have studied 235 strains of E. 
coli producers of ESBLs, and found that 87.3 % of the strains 
were carriers of the gene CTX-M, 77% were carrying TEM gene, 
and 3.8% were carriers of the gene SHV. In addition, few strain 
produced VEB-1 and OXA-10, and non of the isolate produced 
of PER and GES (19).
The general susceptibility pattern of ESBL producer strains to 
antibiotics has decreased in recent years in many countries 
(15,17,20). However, the present study showed high suscepti-
bility patterns to the most effective antibiotics used against 
E. coli producers of ESBLs. In addition, E.coli producer of ES-
BLs have mostly a reduced susceptibility to the trimethoprim 
- sulfamethoxazole (19.2%), whereas other studies conduct-
ed in Bahrain and in Khartoum have shown different results 
(21,22,23). But on the other site, this study revealed an alarming 
decrease in the susceptibility of our isolates to the quinolones 
and the fluoroquinolones (table 3). Similar results are found in 
a study previously conducted in Lebanon (15), whereas other 
studies carried out in the Middle East areas have shown higher 
susceptibility rates of their isolates to fluoroquinolones (24, 25).
It is important to note that 23.3% of our isolates were suscep-
tible to the clavulanic acid associated with the amoxicillin or 
ticarcillin, whereas this percentage increased significantly in 
the case of tazobactam associated with the piperacillin (82.2%). 
Our results show a similarity with a study conducted by Oliver 
et al. 2002 (25). The susceptibility of our isolates to cefoxitin 
was 82.2%, which is similar to a study performed in Iran by 
Mehrgan et al. 2008 (24).
With regards to the aminoglycosides, our results showed that 
amikacin remains the most active drug (81.4%) against tested 
E.coli strains. Kader et al. 2005, have shown a similar result in 
their study conducted in Saudi Arabia (27).
This study has also demonstrated that 58/73 (79.5%) of E. coli 
strains which produced ESBLs, were isolated from urine; which 
indicates the highly occurrence of these strains in urinary tract 
infections. A previous study from the Calgary Health Region in 
Canada, demonstrated that CTX-M-producing E. coli is emerg-
ing as an important cause of community-onset urinary tract 
infections (27). Pitout, JD et al. 2008, have documented that 
extended-spectrum ß-lactamase producing Enterobacteriace-
ae are becoming an emerging public-health concern (28).
It should be noted that the percentage of E. coli resistance to 
ampicillin, aminoglycosides, tetracycline, chloramphenicol and 
sulphonamides is lower in the industrialized countries than in 
the developing countries (11), since the overuse and the uncon-
trolled use of antibiotics and the low standard of personal and 
community hygiene are favoring the spread of resistant strains 
between humans in the developing countries.
Conclusion
This study confirms the large dissemination of the gene CTX-M 
among E. coli in the North Lebanon, and the results of antibi-
otic susceptibility revealed a high rates of resistance against 
the quinolones and the fluoroquinolones which are widely 
used in treatment of the urinary tract infections in Lebanon. 
These results should draw the attention of the Lebanese medi-
cal authorities to the serious consequences of increasing anti-
microbial resistance, therefore, it is import to increase efforts 
to monitor and control the spread of antimicrobial resistant 
strains in hospitals and community.
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